NKMAX Co., Ltd. Logo

NKMAX Co., Ltd.

Biotech firm for NK cell therapies, global research reagents, diagnostics, and supplements.

182400 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 돌마로 172 정자동, 헬스케어혁신파크 1층및6층, 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

NKMAX Co., Ltd. is a biotechnology company specializing in technologies centered on Natural Killer (NK) cells. The company's operations span multiple segments, including the development of NK cell-based immunotherapies for cancer and other diseases. It is a key global manufacturer and supplier of high-quality research reagents, providing recombinant proteins and monoclonal antibodies to over 2,000 research institutions and diagnostic firms worldwide. Additionally, NKMAX offers a precision diagnostic test to quantify NK cell activity for immune function assessment and markets a line of dietary supplements, such as NK365, designed to support the immune system.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for NKMAX Co., Ltd. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-04 00:00
Legal Proceedings Report
회생절차종결결정
Korean 8.5 KB
2025-09-03 00:00
Regulatory News Service
기타시장안내 (실질심사 대상여부 결정을 위한 조사기간 연장 안내 )
Korean 3.2 KB
2025-08-25 00:00
Legal Proceedings Report
회생절차종결신청
Korean 12.4 KB

Automate Your Workflow. Get a real-time feed of all NKMAX Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for NKMAX Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Develops therapies for rare genetic diseases, CNS disorders, and regenerative medicine.
Japan 4552
JEIL PHARMACEUTICAL CO.,LTD Logo
Global manufacturer of pharmaceutical APIs, antibiotics, and injection-based treatments.
South Korea 271980
JEIL PHARMA HOLDINGS INC. Logo
Develops and distributes APIs, generics, and modified drugs, specializing in injections.
South Korea 002620
JETEMA Co.,Ltd. Logo
Research-driven developer of aesthetic toxins, dermal fillers, and threads.
South Korea 216080
Develops and manufactures high-tech drugs for cancer, diabetes, and a range of diseases.
South Korea 007370
JW LIFESCIENCE CORPORATION Logo
A leading developer and manufacturer of infusion solutions, from basic IV fluids to complex nutrients.
South Korea 234080
JW SHINYAK CORPORATION Logo
Develops specialty medicines for the dermatology, urology, and otolaryngology clinical markets.
South Korea 067290
Kadimastem Ltd. Logo
Develops off-the-shelf stem cell therapies for diabetes & neurodegenerative diseases.
Israel KDST
kainos loboratories,inc Logo
Develops, manufactures, and sells innovative clinical diagnostic reagents for the healthcare industry.
Japan 4556
KAKEN PHARMACEUTIAL CO., LTD. Logo
R&D pharma firm creating drugs & devices for orthopedics, dermatology, and surgery globally.
Japan 4521

Talk to a Data Expert

Have a question? We'll get back to you promptly.